New device could spare colon cancer patients from temporary stoma

NCT ID NCT06540807

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a temporary device called Colovac 2 in 24 people undergoing colon cancer surgery. The device is placed inside the bowel to protect the surgical connection while it heals, potentially avoiding the need for a temporary stoma. Researchers checked if the device stayed in place and was safe over 10 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Colovac 2 colorectal anastomosis protection device
What this could lead to
If successful, this device could allow surgeons to avoid creating a temporary stoma in many patients, reducing recovery time and complications.
What could go wrong
This is a small, early feasibility study with only 24 participants. The device may not work as intended, and risks like device migration or infection remain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

24 people

The number who actually took part.

Started

Jul 2024

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age or older * Eligible to undergo open or minimally invasive sphincter-sparing low anterior resection with planned diverting loop ileostomy for malignancy, based on multidisciplinary team recommendations * Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2History of left sided colitis * Willingness to comply with protocol-specific treatment and study visits and to sign a written Informed Consent Form Exclusion Criteria: * History of left sided colitis * Known allergy to nickel or other components of the Colovac 2 System * Pregnant or nursing female subject * Concomitant major surgical procedure in combination with Colorectal resection (i.e., hepatectomy) * Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation, impair the ability of the participant to undergo protocol described procedures or interfere with the interpretation of study results including, but not limited to: * Stage IV colorectal cancer unless curative intent R0 resection is planned AND there is no associated peritoneal disease * Immunodeficiency (CD4+ count \< 500 CU MM) * Systemic steroid therapy within the past 6 months * Systemic infection at the time of surgery or requiring systemic antimicrobial therapy up to 1 week before surgery * Major surgical or interventional procedures within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study * Diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, intraabdominal infection, ischemic bowel, carcinomatosis * Fecal incontinence, involvement of sphincter by the neoplastic disease or evidence of extensive local disease in the pelvis seen on pre-operative imaging * Severe malnutrition which is defined as at least 10% weight loss within 3 months prior to enrollment. * Occurrence of any of the following during the colorectal surgery: 1. Blood loss (\>750 cc) 2. Blood transfusion 3. Any new sign of ischemia 4. Positive air leak test 5. Inadequate bowel preparation 6. Anastomosis location greater than 15 cm from the anal verge 7. Other intra-operative risks that preclude the subject from undergoing the procedure with the investigational device

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colon cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AKFA

    Tashkent, Uzbekistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.